Even after the S-1. The float and AS still reasonably low for a biotech with a novel pipeline and sought after patent (look at the collaberators and partners).....and how many biotechs out their can lay claim to a founder who won the Nobel prize in medicine??:http://en.m.wikipedia.org/wiki/Craig_Mello
"Mello is involved in several RNAi-based biotechnological companies. He is a co-founder and the scientific advisory board member of RXi Pharmaceuticals "